Fanapt salesforce

Discussion in 'Novartis' started by Anonymous, Mar 9, 2010 at 6:06 PM.

Tags: Add Tags
  1. Anonymous

    Anonymous Guest

    Anyone know what type of salesforce Novartis has put together to market Fanapt? Have been hearing around 120 reps so far...
     

  2. Anonymous

    Anonymous Guest

    There is approx. 300. Most pulled from Neuroscience or CV division. Most seem competent.
     
  3. Anonymous

    Anonymous Guest

    What's been physician reaction, are they interested at all? been any uptake?
     
  4. Anonymous

    Anonymous Guest

    1) Indifferent

    2) No

    3) No

    I got pulled from CV and I would rather be dead than work tomorrow if that tells you anything. In fact, I may resign tomorrow with no job in hand and nothing whatsoever on the horizon I am so Goddamn miserable.
     
  5. Anonymous

    Anonymous Guest

    BS, complete BS. You couldn't sell used Toyotas on the side if you wanted to, so you better keep your day job.
     
  6. Anonymous

    Anonymous Guest

    Would rather sell toyota than Fanapt !!! Ha, Ha, ha, we warned you all and that Liz RD SUCKS! Good luck dumb Fu#$!
     
  7. Anonymous

    Anonymous Guest

    Check this out. Good selling!!!!

    Novartis and Vanda Pharma's Schizophrenia Treatment May Be DOA
    By David Phillips | Mar 9, 2010

    Vanda Pharmaceuticals (VNDA) is hoping to convince psychiatrists that its new schizophrenia treatment Fanapt is more than just another “me-too” antipsychotic. Even a licensing deal with Novartis (NVS), however, is unlikely to dramatically alter doctors’ prescribing habits.

    Fanapt (iloperidone) doesn’t offer any unique chemical properties that separate it from the other second-generation atypical antipsychotics (so-named because of a lower risk of movement disorders side effects). Like other second-generation atypicals (SGAs), Fanapt is proposed to produce its therapeutic effects via mixed affinity and receptor blockade of dopamine and serotonin, two neurotransmitters involved in regulating brain function. Clinical differences among SGAs in the ability to diminish psychotic symptoms of schizophrenia, such as auditory hallucinations and delusions, are thought related to extent (and duration) of receptor selectivity and affinity (in addition to a postulated genomic factors).

    Pharmacology evidence suggests Fanapt more closely resembles Pfizer’s SGA Geodon (ziprasidone) — both drugs even carry warnings in their package insert discussing the risk of heart arrhythmias.

    Novartis launched Fanapt in the US in January 2010, per its previously announced drug pact with Vanda (worth up to $465 million). Vanda has retained rights outside North America (since it has no sales infrastructure, look for the company to license drug rights ex-stateside, too).

    A needs assessment suggests a bumpy launch ahead for Fanapt:

    The drug is the ninth SGA to hit the market and offers few efficacy advantages over existing therapies;
    Unlike most competitive alternatives, titration to the therapeutic dose must be done slowly (delaying desired control of schizophrenia symptoms), as the drug is an alpha-adrenergic blocker — which means an unsuspecting patient carelessly dosed could keel over from a dramatic drop in blood pressure; and,
    The drug - unlike other SGAs - is not indicated for treatment of co-morbid conditions common to schizophrenia, such as anxiety or bipolar disorder, limiting its utlity.
     
  8. Anonymous

    Anonymous Guest

    If you see lay off or getting fired on the near horizon then wait. Otherwise get out, I got fired and got some severance, I have no job but have never been happier, can't wait for March Madness without work. Believe me there is not a ton of jobs out there but they are there. It is much easier to network and find a job when you are unemployed.
     
  9. Anonymous

    Anonymous Guest

    Elizabeth Johnson - She's not only a fat Bi#$%! RD working the East Coast, she also a client who was in clinical trials and still using the drug!
     
  10. Anonymous

    Anonymous Guest

    The needs assessment question is simply at what point does the extreme cost to sell this dog and the minimal sales require an major adjustment?
     
  11. Anonymous

    Anonymous Guest

    But at least we have Elizabeth "LIZ" Johnson that useless East RD ho has NO clue what she is doing! She's as good a resource and a "Black Box Warning"!!! What a waste of space, where the hell did she come from??? Better yet, how did she get here???
     
  12. Anonymous

    Anonymous Guest

    OK, you definitely have some issues with Liz but why don't you just come out and say what they are. Is it Liz? or is it something that was going to happen no matter what? Your rants and raves are getting personal - just get to the point - what's bothering you?
     
  13. Anonymous

    Anonymous Guest

    Well Liz it's like this......since you want to come out here and ask. You are not bright and have no idea how to lead. Thanks for asking....
     
  14. Anonymous

    Anonymous Guest

    Thanks to Michael Braun our stupid Fanapt Brand Team director for sinking Fanapt. Michael has taken our Fanapt Sales force down with him. How did Novartis ever hire Michael Braun to be a Brand Team Director? No worries Michael, just blame us Sales Reps for your poor performance and cut our bonus checks.
     
  15. Anonymous

    Anonymous Guest

    So, it is safe to assume that you are not a "FAN?"
     
  16. Anonymous

    Anonymous Guest

    Boy talk about someone with a chip on his shoulder...

    Pilla is the person responsible. Braun is part of the extended team. You...are a moron. Funny to see you doing this on three separate threads. Jealous, I guess.
     
  17. Anonymous

    Anonymous Guest

    YOU just posted on 4 threads between 5:10 and 5:17 and said the EXACT same thing. Obviously you cannot think past one thought in any 2 minute increment. (Who is a moron?)

    FACT: This drug, for what ever reason you attribute it to, is not performing any where near what was expected. Most of us are not participating in the blame game. We are looking for information on organizational structual changes and other useful information. Let's face it, stockholders will not tolerate this type of return on investment.
     
  18. Anonymous

    Anonymous Guest

    Lisa, Braun and Liz ??? What a motley crew. Talk about no emotion, lack of leadership-salesmanship? Oh yes Let talk about the ASM's and the 2 x month field ride alongs? What is up with this. ROI... Why do we ride with ASM's Whats up with that? Why not save dollars and put these people to work! really. FANAPT is DEAD. No good press anywhere. Novartis SALES MANAGEMENT-Leadership never does anything different, no trust, very elementary, pharma 101. Fanapt is a bust! We are all going down. No MS positions, nothing but a boot for being a performer. Low salary folks may have a chance to stay. FANAPT TEAM is a waste.
     
  19. Anonymous

    Anonymous Guest

    NOT a fan.
     
  20. Anonymous

    Anonymous Guest

    so what will NVS do? Layoff for just Fanapt? or will they do a combo layoff? Nuero and some Fanapt? Or, no layoffs and move folks over to MS? interesting speculation...